Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.43 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.30 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL233626 | 1.00 | MAPT (0.46) | MAPTSIGMAR1OPRD1CHRM2CHRM1 | |
| SCHEMBL7095655 | 1.00 | MAPT (0.46) | MAPTSIGMAR1OPRD1CHRM2CHRM1 | |
| SCHEMBL231228 | 1.00 | MAPT (0.46) | MAPTSIGMAR1OPRD1CHRM2CHRM1 | |
| SCHEMBL14343414 | 1.00 | MAPT (0.46) | MAPTSIGMAR1OPRD1CHRM2CHRM1 | |
| SCHEMBL14343776 | 1.00 | MAPT (0.46) | MAPTSIGMAR1OPRD1CHRM2CHRM1 | |
| SCHEMBL3851995 | 0.79 | — | — | |
| SCHEMBL13770623 | 0.75 | SIGMAR1 (0.47) | MAPTSIGMAR1CHRM2CHRM1 | |
| SCHEMBL6376833 | 0.75 | SIGMAR1 (0.47) | MAPTSIGMAR1CHRM2CHRM1 | |
| SCHEMBL3106152 | 0.75 | SIGMAR1 (0.47) | MAPTSIGMAR1CHRM2CHRM1 | |
| SCHEMBL26060560 | 0.75 | SIGMAR1 (0.47) | MAPTSIGMAR1CHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12297323-B2 | Polysiloxane vinylic crosslinkers with high refractive index | ALCON INC. (CH) | 2025-05-13 | — | — | US | disclosed |
| EP-4314118-B1 | POLYSILOXANE VINYLIC CROSSLINKERS WITH HIGH REFRACTIVE INDEX | ALCON INC (CH) | 2025-04-30 | — | — | EP | disclosed |
| CN-117915903-A | Compounds for the treatment of neurodegenerative, degenerative and metabolic disorders and uses thereof | 佛罗里达大学研究基金会公司 | 2024-04-19 | — | — | CN | disclosed |
| US-20240124466-A1 | COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE, DEGENERATIVE AND METABOLIC DISORDERS | THE SCRIPPS RESEARCH INSTITUTE | 2024-04-18 | — | — | US | disclosed |
| US-11945895-B2 | Photochromic polydiorganosiloxane vinylic crosslinkers | ALCON INC. (CH) | 2024-04-02 | — | — | US | disclosed |
| CN-115605529-B | Photochromic polydiorganosiloxane vinyl cross-linking agent | 爱尔康公司 | 2024-03-26 | — | — | CN | disclosed |
| EP-4118134-B1 | PHOTOCHROMIC POLYDIORGANOSILOXANE VINYLIC CROSSLINKERS | ALCON INC (CH) | 2024-02-28 | — | — | EP | disclosed |
| EP-4314118-A1 | POLYSILOXANE VINYLIC CROSSLINKERS WITH HIGH REFRACTIVE INDEX | Alcon Inc. (CH) | 2024-02-07 | — | — | EP | disclosed |
| EP-4259118-A1 | COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE, DEGENERATIVE AND METABOLIC DISORDERS | The Scripps Research Institute (US) | 2023-10-18 | — | — | EP | disclosed |
| CN-116888193-A | Polysiloxane vinyl cross-linking agent with high refractive index | 爱尔康公司 | 2023-10-13 | — | — | CN | disclosed |
| US-5807858-A | DIARYLMETHYLPIPERAZINE AND PIPERIDINE COMPOUNDS; SIDE EFFECTREDUCTION OF ANALGESICS | DELTA PHARMACEUTICAL, INC. (US) | 1998-09-15 | — | — | US | disclosed |
| WO-1997046240-A1 | COMPOSITIONS AND METHODS FOR REDUCING RESPIRATORY DEPRESSION | DELTA PHARMACEUTICALS, INC. (US) | 1997-12-11 | — | — | WO | disclosed |
| US-5681830-A | DIARYLMETHYL PIPERAZINE COMPOUNDS HAVING UTILITY IN MEDICAL THERAPY AS RECEPTOR-BINDING SPECIES | DELTA PHARMACEUTICALS, INC. (US) | 1997-10-28 | — | — | US | disclosed |
| US-5658908-A | RECEPTOR BINDING SPECIES FOR MEDIATING ANALGESIA, COMBATTING DRUG ADDICTION, DRUG OVERDOSE | DELTA PHARMACEUTICALS, INC. (US) | 1997-08-19 | — | — | US | disclosed |
| US-5574159-A | DIARYLMETHYL PIPERAZINES, RECEPTOR BINDING | DELTA PHARMACEUTICALS, INC. (US) | 1996-11-12 | — | — | US | disclosed |
| US-5552404-A | COMPOUNDS FOR NEUROTRANSMITTERS FOR ANIMALS | DELTA PHARMACEUTICALS, INC. (US) | 1996-09-03 | — | — | US | disclosed |
| EP-0711289-A1 | PIPERAZINE COMPOUNDS USED IN THERAPY | DELTA PHARMACEUTICALS, INC. (US) | 1996-05-15 | — | — | EP | disclosed |
| EP-0649414-A1 | OPIOID DIARYLMETHYLPIPERAZINES AND PIPERIDINES | THE WELLCOME FOUNDATION LIMITED (GB) | 1995-04-26 | — | — | EP | disclosed |
| WO-1995004051-A1 | PIPERAZINE COMPOUNDS USED IN THERAPY | THE WELLCOME FOUNDATION LIMITED (GB) | 1995-02-09 | — | — | WO | disclosed |
| WO-1993015062-A1 | OPIOID DIARYLMETHYLPIPERAZINES AND PIPERIDINES | THE WELLCOME FOUNDATION LIMITED (GB) | 1993-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240124466-A1 | COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE, DEGENERATIVE AND METABOLIC DISORDERS | SNCA, NLN, HTT | MAPT 12/4885SIGMAR1 1324/4885OPRD1 1938/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.